Gosset Ownership
Private
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
QurCan Therapeutics General Information
QurCan Therapeutics has developed a next-generation hybrid polymer-lipid nanoparticle platform called TERP that enables safe and tissue-selective delivery of biologic drugs—including RNAs, peptides, and antibodies—to extra-hepatic sites such as the brain and spleen. The company’s technology addresses challenges with current lipid nanoparticles by improving drug release profiles and reducing liver accumulation. Their lead programs are focused on precision medicine for solid-tumor cancer therapy and CNS diseases. As of 2024–2025 public sources indicate preclinical development; no clinical trial results have been published yet
Contact Information
Website
Primary Industry
Biotech
Corporate Office
Toronto or Mississauga area inferred from context; exact city not explicitly stated in all sources., Ontario
Canada
Canada
Drug Pipeline
No pipeline data available
Key Partnerships
QurCan Therapeutics Funding
No funding data available
To view QurCan Therapeutics's complete valuation and funding history, request access »